Newsroom
Featured News
- Investors14 March 2024
Lotus marked historical high for 2023 revenues, profit and cash dividend
- Investors08 March 2024
Lotus Reported Unaudited February Revenues of NT$1,052 Million
- Investors07 February 2024
Lotus Reported Unaudited January Revenues of NT$1,996 Million, surging 45.4% MoM
- Investors10 January 2024
Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth
- Business11 December 2023
Lotus and Intas Announce Strategic Partnership to Commercialize Denosumab Biosimilar in Asia
- Business11 December 2023
Lotus and Favorex Pte Ltd Announces Strategic Partnership to Commercialize an Ustekinumab Biosimilar in South Korea
- Investors08 December 2023
Lotus Reported Unaudited November Consolidated Revenues of NT$1,135 million, representing 25% MoM Growth and 6% YoY Growth
- Business07 December 2023
Lotus Pharmaceutical Announces First Shipment of Lenalidomide to Japan
- Investors10 November 2023
Lotus Reported Unaudited October Consolidated Revenues of NT$912 million, Marking a Nearly 10% YoY Growth Accumulated Unaudited Consolidated Revenue for the Frist Ten Months Recorded NT$14.45 billion, with 17.58% YoY Growth